Valuation: ProSomnus, Inc.

Market Cap 237K 208K 197K 178K 335K 22.71M 337K 2.36M 910K 11.59M 888K 869K 37.24M P/E 2022
-7.8x
P/E 2023 -0.66x
Enterprise Value 35.24M 31M 29.31M 26.58M 49.93M 3.38B 50.22M 351M 136M 1.73B 132M 129M 5.55B EV / Sales 2022
5.49x
EV / Sales 2023 1.85x
Free-Float
90.18%
Yield 2022 *
-
Yield 2023 -
3 years 0
Extreme 0.004
1.36
5 years 0
Extreme 0.004
11.3
10 years 0
Extreme 0.004
11.3
Manager TitleAgeSince
Chief Executive Officer 52 02/05/2022
Chief Tech/Sci/R&D Officer 45 02/05/2022
Director of Finance/CFO 57 28/02/2023
Date Insider Type Main position Quantity % Market Cap. Importance
15/02/24 Free

Founder

315,742 1.9254%
15/02/24 Free

Chief Financial Officer

315,742 1.9254%
15/02/24 Free

Chief Executive Officer

1,322,756 8.0663%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-98.61% 237K
+2.01%+2.01%-34.08%+17.19% 3.64B
+3.65%+13.56%+15.62% - 1.62B
+3.46%+1.07%+115.57% - 909M
-6.10%-14.65% - - 317M
+1.02%-1.40%-17.56%-5.19% 138M
+6.62%+10.47%+85.55%+53.72% 121M
Average +1.52%+4.97%+27.52%-8.22% 963.01M
Weighted average by Cap. +2.28%+5.12%+2.22%+17.53%

Financials

2022 2023
Net sales 19.39M 17.06M 16.13M 14.63M 27.47M 1.86B 27.63M 193M 74.58M 950M 72.81M 71.23M 3.05B 27.65M 24.32M 23M 20.86M 39.17M 2.65B 39.4M 275M 106M 1.35B 104M 102M 4.35B
Net income -7.15M -6.28M -5.94M -5.39M -10.12M -686M -10.18M -71.15M -27.48M -350M -26.83M -26.25M -1.12B -24.1M -21.19M -20.04M -18.18M -34.13M -2.31B -34.33M -240M -92.66M -1.18B -90.46M -88.5M -3.79B
Net Debt 17.17M 15.1M 14.28M 12.95M 24.32M 1.65B 24.46M 171M 66.02M 841M 64.45M 63.05M 2.7B 35.01M 30.79M 29.11M 26.41M 49.59M 3.36B 49.88M 349M 135M 1.71B 131M 129M 5.51B
Logo ProSomnus, Inc.
ProSomnus, Inc. is a medical technology company. The Company is focused on the development, manufacturing and marketing of precision intraoral medical devices, a novel non-invasive option for treating and managing patients with obstructive sleep apnea (OSA). Its intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. The Company's devices have demonstrated efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. Its precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide.
Employees
136
  1. Stock Market
  2. Stocks
  3. LAAA Stock